Press Release History - 2013

  • 4 Jan 2013
    ThromboGenics Confirms JETREA® US Launch Date of Monday January 14th, 2013
  • 18 Jan 2013
    ThromboGenics receives positive CHMP opinion for JETREA®
  • 28 Feb 2013
    New Paper in Cell highlights the potential role of TB-403 (anti-PlGF) in the treatment of medulloblastoma, a pediatric brain tumor
  • 14 Mar 2013
    ThromboGenics Announces Business Update and 2012 Full-Year Results
  • 15 Mar 2013
    ThromboGenics’ JETREA® granted EU approval for vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns
  • 18 Mar 2013
    ThromboGenics Starts Trading as Part of the BEL20 Index Today
  • 11 Apr 2013
    ThromboGenics’ JETREA®, the first and only medicine for treating vitreomacular traction, now launched in the UK
  • 24 Apr 2013
    ThromboGenics’ CEO to Participate in BIO 2013 Interactive Panel: Success Stories: ‘How Emerging Belgian Biotechs are Going Public’
  • 2 May 2013
    ThromboGenics’ JETREA® available in Germany public and private market
  • 3 May 2013
    ThromboGenics NV increases share capital through warrant exercises
  • 16 May 2013
    ThromboGenics Business Update